Year-by-year prevalence of elevated free κ FLC, free λ FLC, or both
| . | Patients with a normal FLC ratio and without an M-protein (n = 61) . | All patients (n = 109) . | ||||
|---|---|---|---|---|---|---|
| N . | n . | Percentage (95% CI) . | N . | n . | Percentage (95% CI) . | |
| Blood draw before CLL diagnosis, y | ||||||
| 1 | 30 | 4 | 13 (4-31) | 59 | 20 | 34 (22-47) |
| 2 | 33 | 7 | 21 (9-39) | 56 | 17 | 30 (19-44) |
| 3 | 29 | 7 | 24 (10-44) | 59 | 21 | 36 (24-49) |
| 4 | 33 | 6 | 18 (7-35) | 55 | 16 | 29 (18-43) |
| 5 | 28 | 6 | 21 (8-41) | 50 | 19 | 38 (25-53) |
| 6 | 24 | 6 | 25 (10-47) | 43 | 14 | 33 (19-49) |
| 7 | 16 | 2 | 13 (2-38) | 29 | 7 | 24 (10-44) |
| 8 | 13 | 1 | 8 (0.2-36) | 23 | 6 | 26 (10-48) |
| 9 | 7 | 1 | 14 (0.4-58) | 9 | 1 | 11 (0.3-48) |
| 10 | 7 | 0 | 0 | 8 | 1 | 13 (0.3-53) |
| P trend | .145 | .038 | ||||
| . | Patients with a normal FLC ratio and without an M-protein (n = 61) . | All patients (n = 109) . | ||||
|---|---|---|---|---|---|---|
| N . | n . | Percentage (95% CI) . | N . | n . | Percentage (95% CI) . | |
| Blood draw before CLL diagnosis, y | ||||||
| 1 | 30 | 4 | 13 (4-31) | 59 | 20 | 34 (22-47) |
| 2 | 33 | 7 | 21 (9-39) | 56 | 17 | 30 (19-44) |
| 3 | 29 | 7 | 24 (10-44) | 59 | 21 | 36 (24-49) |
| 4 | 33 | 6 | 18 (7-35) | 55 | 16 | 29 (18-43) |
| 5 | 28 | 6 | 21 (8-41) | 50 | 19 | 38 (25-53) |
| 6 | 24 | 6 | 25 (10-47) | 43 | 14 | 33 (19-49) |
| 7 | 16 | 2 | 13 (2-38) | 29 | 7 | 24 (10-44) |
| 8 | 13 | 1 | 8 (0.2-36) | 23 | 6 | 26 (10-48) |
| 9 | 7 | 1 | 14 (0.4-58) | 9 | 1 | 11 (0.3-48) |
| 10 | 7 | 0 | 0 | 8 | 1 | 13 (0.3-53) |
| P trend | .145 | .038 | ||||
N indicates number of participants with blood draw at each time point in relation to the diagnosis of CLL; and n, number of participants with elevated levels of free κ FLC (defined as more than 1.94 mg/dL), elevated levels of free λ FLC (defined as more than 2.63 mg/dL), or both.